hormônios femininos e hemostasia female hormones and hemostasis

Clicks: 365
ID: 228656
2007
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #33 of 101 articles by views in 2018 international conference on information technologies, infotech 2018 - proceedings

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Os hormônios femininos exógenos utilizados para contracepção ou para terapia hormonal (TH) no climatério estão associados a aumento de risco para tromboembolismo venoso (TEV), principalmente por provocarem alterações pró-coagulantes na hemostasia. Este risco não é cumulativo e parece ser maior no primeiro ano de uso. A dose de estrogênio, o tipo de estrogênio e progestagênio utilizados, a via de administração hormonal e os fatores de risco hereditários para trombose venosa de cada paciente interferem no risco final para trombose venosa. O conhecimento dos efeitos na hemostasia inerentes a cada composto hormonal é essencial para uma prescrição adequada.
Exogenous female hormones used for contraception or postmenopausal hormonal replacement therapy are associated with an increase of venous thromboembolism (VTE) risk, mainly because they cause a hypercoagulable state. The risk is highest during the first year of use and it is not cumulative. The dose of estrogen, the type of estrogen and progestogen, the route of administration of female sex steroid hormones, and the hereditary risk factors for VTE of each patient can interfere on the final risk for VTE. The knowledge of their effect on hemostasis is essential for a correct prescription.
Reference Key
vieira2007revistahormnios Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors ;Carolina Sales Vieira;Luciana Correa Oliveira de Oliveira;Marcos Felipe Silva de Sá
Journal 2018 international conference on information technologies, infotech 2018 - proceedings
Year 2007
DOI
10.1590/S0100-72032007001000008
URL
http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-72032007001000008
Keywords
thromboembolism hemostasis oral hormone replacement therapygynecology and obstetrics contraceptivos orais

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.